# Sera Prognostics, Inc.: overview SERA · Nasdaq · CIK 1534969 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/sera.md) · [Financials](/companies/sera/financials.md) · [Filings](/companies/sera/filings.md) · [Insiders](/companies/sera/insiders.md) Latest reported revenue: [$30.0k](/filings/0001193125-26-346862.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 12, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-346862). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | [29.0](/filings/0001193125-25-280182.md) | [24.0 d](/filings/0001534969-26-000009.md) | [38.0](/filings/0001534969-26-000025.md) | [17.0](/filings/0001193125-26-346862.md) | [16.0](/filings/0001193125-25-280182.md) | [10.0 d](/filings/0001534969-26-000009.md) | [14.0](/filings/0001534969-26-000025.md) | [30.0](/filings/0001193125-26-346862.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(30558.6%)](/filings/0001193125-25-280182.md) | [(39262.5%) d](/filings/0001534969-26-000009.md) | [(24342.1%)](/filings/0001534969-26-000025.md) | [(54823.5%)](/filings/0001193125-26-346862.md) | [(56125.0%)](/filings/0001193125-25-280182.md) | [(89540.0%) d](/filings/0001534969-26-000009.md) | [(66857.1%)](/filings/0001534969-26-000025.md) | [(33346.7%)](/filings/0001193125-26-346862.md) | | Net margin | % | [(27306.9%)](/filings/0001193125-25-280182.md) | [(35745.8%) d](/filings/0001534969-26-000009.md) | [(21544.7%)](/filings/0001193125-26-346862.md) | [(47329.4%)](/filings/0001193125-26-346862.md) | [(48837.5%)](/filings/0001193125-25-280182.md) | [(78810.0%) d](/filings/0001534969-26-000009.md) | [(59992.9%)](/filings/0001193125-26-346862.md) | [(30463.3%)](/filings/0001193125-26-346862.md) | | Diluted EPS | $ per share | [(0.24)](/filings/0001193125-25-280182.md) | not reported | [(0.20)](/filings/0001534969-26-000025.md) | [(0.16)](/filings/0001193125-26-346862.md) | [(0.16)](/filings/0001193125-25-280182.md) | not reported | [(0.17)](/filings/0001534969-26-000025.md) | [(0.18)](/filings/0001193125-26-346862.md) | | Free cash flow | $k | [(7,021) d](/filings/0001193125-25-280182.md) | [(6,268) d](/filings/0001534969-26-000009.md) | [(7,556)](/filings/0001534969-26-000025.md) | [(5,754) d](/filings/0001193125-26-346862.md) | [(6,589) d](/filings/0001193125-25-280182.md) | [(6,450) d](/filings/0001534969-26-000009.md) | [(8,782)](/filings/0001534969-26-000025.md) | [(6,327) d](/filings/0001193125-26-346862.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.1](/filings/0001534969-23-000030.md) | [0.3](/filings/0001534969-24-000055.md) | [0.3](/filings/0000950170-25-042017.md) | [0.1](/filings/0001534969-26-000009.md) | [0.1](/filings/0001534969-26-000009.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(43164.6%)](/filings/0001534969-23-000030.md) | [(17034.3%)](/filings/0001534969-24-000055.md) | [(13013.4%)](/filings/0000950170-25-042017.md) | [(47577.9%)](/filings/0001534969-26-000009.md) | [(45066.7%)](/filings/0001534969-26-000009.md) | | Net margin | % | [(42693.9%)](/filings/0001534969-23-000030.md) | [(16487.3%)](/filings/0001534969-24-000055.md) | [(11843.8%)](/filings/0000950170-25-042017.md) | [(42724.7%)](/filings/0001534969-26-000009.md) | [(39417.3%)](/filings/0001534969-26-000009.md) | | Diluted EPS | $ per share | [(2.33)](/filings/0001534969-23-000030.md) | [(1.43)](/filings/0001534969-24-000055.md) | [(1.16)](/filings/0000950170-25-042017.md) | [(0.99)](/filings/0001534969-26-000009.md) | [(0.67)](/filings/0001534969-26-000009.md) | | Free cash flow | $m | [(32.9)](/filings/0001534969-23-000030.md) | [(35.4)](/filings/0001534969-24-000055.md) | [(27.3)](/filings/0000950170-25-042017.md) | [(14.2)](/filings/0001534969-26-000009.md) | [(26.3)](/filings/0001534969-26-000009.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/sera/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $10.0m | 5,498,170 | | Unchanged | | [Whetstone Capital Advisors, LLC](/funds/1607278.md) | 2026-06-30 | $6.0m | 3,306,889 | | Unchanged | | [Aberdeen Group plc](/funds/1716774.md) | 2026-06-30 | $5.0m | 2,753,525 | | Added +202,750 | | [Vivo Capital, LLC](/funds/1674712.md) | 2026-06-30 | $3.0m | 1,650,440 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $2.4m | 1,297,792 | | Added +93,677 | | [CAPTRUST FINANCIAL ADVISORS](/funds/1512024.md) | 2026-06-30 | $975.1k | 535,755 | | Reduced −1,006 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $635.5k | 348,967 | | Reduced −14,650 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $402.9k | 221,369 | | Added +25,264 | | [AWM Investment Company, Inc.](/funds/1535264.md) | 2026-06-30 | $377.4k | 207,382 | | Unchanged | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $311.1k | 170,908 | | Added +1,247 | ## Recent filings [All 657 filings](/companies/sera/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-19 | 21:05 ET | [8-K](/filings/0001193125-26-357112.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-357112 | | 2026-08-12 | 20:11 ET | [10-Q](/filings/0001193125-26-346862.md) | Quarterly report, period 2026-06-30 | 0001193125-26-346862 | | 2026-08-12 | 20:08 ET | [8-K](/filings/0001193125-26-346846.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-346846 | | 2026-06-30 | 20:09 ET | [8-K](/filings/0001534969-26-000035.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001534969-26-000035 | | 2026-06-04 | 21:13 ET | [8-K](/filings/0001534969-26-000032.md) | 5.07 Shareholder vote results | 0001534969-26-000032 | | 2026-06-01 | 20:44 ET | [8-K](/filings/0001534969-26-000028.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001534969-26-000028 | | 2026-05-06 | 20:08 ET | [10-Q](/filings/0001534969-26-000025.md) | Quarterly report, period 2026-03-31 | 0001534969-26-000025 | | 2026-05-06 | 20:06 ET | [8-K](/filings/0001534969-26-000024.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001534969-26-000024 | | 2026-04-24 | 20:10 ET | [DEF 14A](/filings/0001534969-26-000018.md) | Proxy statement, period 2026-04-23 | 0001534969-26-000018 | | 2026-03-18 | 20:08 ET | [10-K](/filings/0001534969-26-000009.md) | Annual report, period 2025-12-31 | 0001534969-26-000009 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001534969-26-000009.md), filed Mar 18, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/85915d95-f5d0-4389-a832-29dd7fb0a721) ## About the filer - CIK: 1534969 - Tickers: SERA - Exchange: Nasdaq - SIC code: 8071 Services-Medical Laboratories - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.